BACKGROUND: Low vitamin D serum levels represent an additional risk factor for end-stage renal disease (ESRD)-associated bone disorders. The aim of this study was to evaluate the prevalence of vitamin D defi ciency in both the summer and winter seasons, as well as to defi ne the associated risk factors, and to establish the link between secondary hyperparathyroidism and circulating 25-hydroxy vitamin D (25 [OH]-D) serum levels.METHODS: Seventy-eight hemodialysis (HD)-requiring ESRD outpatients living in Buenos Aires, Argentina, age 57.2 Ϯ 2.07 years (21-86 years) were evaluated at the end of summer (SUM) and the end of winter (WIN). Then 25 (OH)-D, serum calcium (Ca), intact parathormone, ionized Ca (Ca ϩϩ ), phosphate, alkaline phosphatase, creatinine, C-reactive protein, and serum albumin were evaluated. The participants were evaluated according to the 25 (OH)-D levels following KDOQI guidelines. The participants were assigned to 2 groups according to their Karnofsky scores for functional capacity (FC): FC 1-2 (normal physical capacity full-time to only part-time) and FC 3-4 (limited capacity only for self care to needs permanent assistance). CONCLUSIONS: Fifty percent of the HD-requiring ESRD patients showed 25 (OH)-D insuffi ciency/defi ciency. This fi nding was more frequent in winter. Women and older patients were at higher risk. Those individuals displaying optimal 25 (OH)-D levels showed better health indicators for HD-requiring ESRD patients. FC assessed through the Karnofsky score was a useful clinical parameter able to identify patients at risk of 25 (OH)-D defi ciency. In our population, renal disease-associated secondary hyperparathyroidism did not correlate with vitamin D defi ciency.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.